Salivary Ferritin Changes in Patients with COVID-19
High ferritin serum levels can be found in patients with macrophage activation syndrome, and increased serum ferritin due to cytokine storm have been reported in severe COVID-19 patients. Saliva is being increasingly used in COVID-19 tests as a diagnostic sample for virus detection and quantification. This study aimed to evaluate the possible changes in ferritin in saliva in COVID-19 patients. In addition, the effects of different inactivation SARS-CoV-2 treatments in ferritin measurements in saliva, the correlation between ferritin in saliva and serum, and the possible effects of correction of ferritin values by total protein were assessed. Ferritin was measured in saliva from healthy (n = 30) and COVID-19 (n = 65) patients with severe, (n = 18) or mild (n = 47) disease, depending on the need for nasal flow oxygen or assisted respiration. Ferritin was also measured in paired serum and saliva samples (n = 32) from healthy and COVID-19 patients. The evaluated inactivation protocols did not affect the assay's results except the addition of 0.5% SDS. Significantly higher ferritin was found in the saliva of COVID-19 patients (median; 25-75th percentile) (27.75; 9.77-52.2 µg/L), compared with healthy controls (4.21; 2.6-8.08 µg/L). Individuals with severe COVID-19 showed higher ferritin values in saliva (48.7; 18.7-53.9) than mild ones (15.5; 5.28-41.3 µg/L). Significant correlation (r = 0.425; p < 0.001) was found between serum and saliva in ferritin. Ferritin levels were higher in COVID-19 patients in serum and saliva, and the highest values were found in those patients presenting severe symptomatology. In conclusion, ferritin in saliva has the potential to be a biomarker to evaluate severity in patients with COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
International journal of environmental research and public health - 19(2021), 1 vom: 21. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Franco-Martínez, Lorena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9007-73-2 |
|---|
| Anmerkungen: |
Date Completed 13.01.2022 Date Revised 05.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijerph19010041 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335454534 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335454534 | ||
| 003 | DE-627 | ||
| 005 | 20231225225903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijerph19010041 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM335454534 | ||
| 035 | |a (NLM)35010300 | ||
| 035 | |a (PII)41 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Franco-Martínez, Lorena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Salivary Ferritin Changes in Patients with COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2022 | ||
| 500 | |a Date Revised 05.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a High ferritin serum levels can be found in patients with macrophage activation syndrome, and increased serum ferritin due to cytokine storm have been reported in severe COVID-19 patients. Saliva is being increasingly used in COVID-19 tests as a diagnostic sample for virus detection and quantification. This study aimed to evaluate the possible changes in ferritin in saliva in COVID-19 patients. In addition, the effects of different inactivation SARS-CoV-2 treatments in ferritin measurements in saliva, the correlation between ferritin in saliva and serum, and the possible effects of correction of ferritin values by total protein were assessed. Ferritin was measured in saliva from healthy (n = 30) and COVID-19 (n = 65) patients with severe, (n = 18) or mild (n = 47) disease, depending on the need for nasal flow oxygen or assisted respiration. Ferritin was also measured in paired serum and saliva samples (n = 32) from healthy and COVID-19 patients. The evaluated inactivation protocols did not affect the assay's results except the addition of 0.5% SDS. Significantly higher ferritin was found in the saliva of COVID-19 patients (median; 25-75th percentile) (27.75; 9.77-52.2 µg/L), compared with healthy controls (4.21; 2.6-8.08 µg/L). Individuals with severe COVID-19 showed higher ferritin values in saliva (48.7; 18.7-53.9) than mild ones (15.5; 5.28-41.3 µg/L). Significant correlation (r = 0.425; p < 0.001) was found between serum and saliva in ferritin. Ferritin levels were higher in COVID-19 patients in serum and saliva, and the highest values were found in those patients presenting severe symptomatology. In conclusion, ferritin in saliva has the potential to be a biomarker to evaluate severity in patients with COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a ferritin | |
| 650 | 4 | |a non-invasive sample | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Ferritins |2 NLM | |
| 650 | 7 | |a 9007-73-2 |2 NLM | |
| 700 | 1 | |a Cerón, José J |e verfasserin |4 aut | |
| 700 | 1 | |a Vicente-Romero, María R |e verfasserin |4 aut | |
| 700 | 1 | |a Bernal, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Torres Cantero, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Tecles, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez Resalt, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Mónica |e verfasserin |4 aut | |
| 700 | 1 | |a Tvarijonaviciute, Asta |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Subiela, Silvia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of environmental research and public health |d 2004 |g 19(2021), 1 vom: 21. Dez. |w (DE-627)NLM162777434 |x 1660-4601 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2021 |g number:1 |g day:21 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijerph19010041 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2021 |e 1 |b 21 |c 12 | ||